Pakirovid (nirmatrelvir + ritonavir) approved in Japan for COVID 19.
Pfizer, Inc. announced the oral antiviral drug "Pakirovid" for the new coronavirus infection (COVID-19).
The company has obtained special approval based on Article 14-3 of the Pharmaceuticals and Medical Devices Act for the manufacture and sale of "Pack" (generic name: Nirmatrelvir tablets/ritonavir tablets, hereinafter "Pakirovid") in Japan. This drug was submitted for manufacturing and marketing approval to the Ministry of Health, Labor and Welfare on January 14, this year. The Ministry of Health, Labor and Welfare and Pfizer Japan Inc. announced on February 1st that they have signed a final agreement to supply 2 million people with this drug to Japan.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.